VIVEVE MEDICAL, INC.: Nasdaq/NYSE listing notice — Viveve Medical receives Nasdaq delisting notice for bid price and equity non-compliance

VIVEVE MEDICAL, INC.

Nasdaq Staff notified Viveve on Nov 29, 2022 of delisting for failing Bid Price Rule and Equity Rule.
Company failed to regain compliance with $1.00 minimum bid price by Nov 28, 2022 grace period end.
Stockholders' equity as of Sep 30, 2022 fell below $2.5M minimum, triggering second delisting basis.
Viveve intends to request a hearing before Nasdaq Hearings Panel to stay delisting.
Plan to regain compliance may include fundraising and reverse stock split, but no assurance of success.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

VIVEVE MEDICAL, INC. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

November 29, 2022, Viveve Medical, Inc. (the “Company”) received notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the Company’s non-compliance with the minimum bid price and stockholders’ equity requirements for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rules 5550(a)(2) (the “Bid Price Rule”) and 5550(b)(1) (the “Equity Rule”), respectively, the Company’s securities were subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Pane

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

VIVEVE MEDICAL, INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

November 29, 2022, Viveve Medical, Inc. (the “Company”) received notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the Company’s non-compliance with the minimum bid price and stockholders’ equity requirements for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rules 5550(a)(2) (the “Bid Price Rule”) and 5550(b)(1) (the “Equity Rule”), respectively, the Company’s securities were subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Pane

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001437749-22-028334

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.